Zobrazeno 1 - 10
of 104
pro vyhledávání: '"Jeffrey J Pu"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/be6a68d8894f4384b20a06c47a2862c8
Autor:
Xiaoli Liu, Fanggang Ren, Shuo Li, Na Zhang, Jeffrey J. Pu, Hongyu Zhang, Zhifang Xu, Yanhong Tan, Xiuhua Chen, Jianmei Chang, Hongwei Wang
Publikováno v:
Discover Oncology, Vol 14, Iss 1, Pp 1-15 (2023)
Abstract Aims To investigate the mechanism of exosomes' role in the transformation of MDS to AML. Methods Exosomes in culture supernatants of MDS and AML cell lines, were extracted by ultrafiltration and identified in three ways: morphology, size, an
Externí odkaz:
https://doaj.org/article/f13280c35ad844f69aeb0f7d08e4a391
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-5 (2023)
Abstract Myelofibrosis (MF) is a disorder characterized by the proliferation of myeloid precursors, commonly due to overactive JAK signaling. The discovery of the JAK2V617F mutation and subsequent development of JAK inhibitors (JAKi) results in reduc
Externí odkaz:
https://doaj.org/article/553ada29c46b4d01941f42ab8c4d40f5
Autor:
Hao Wang, Kristin N. Berger, Elizabeth L. Miller, Wei Fu, Larisa Broglie, Frederick D. Goldman, Heiko Konig, Su Jin Lim, Arthur S. Berg, Julie-An Talano, Melanie A. Comito, Sherif S. Farag, Jeffrey J. Pu
Publikováno v:
Therapeutic Advances in Hematology, Vol 14 (2023)
Background: Umbilical cord blood hematopoietic stem cells are commonly used for hematopoietic system reconstitution in recipients after umbilical cord blood transplantation (UCBT). However, the optimal conditioning regimen for UCBT remains a topic of
Externí odkaz:
https://doaj.org/article/1b5ba340870e41c18a9bdae650efef85
Autor:
Gongqiang Wu, Shanshan Guo, Qian Luo, Xiaoxia Wang, Wenhai Deng, Guifang Ouyang, Jeffrey J. Pu, Wen Lei, Wenbin Qian
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundsChimeric antigen receptor (CAR)-T cell therapy has achieved unprecedented success in treating hematopoietic malignancies. However, this cell therapy is hampered in treating acute myeloid leukemia (AML) due to lack of ideal cell surface tar
Externí odkaz:
https://doaj.org/article/3260b2b5281b48bab460a6f107e6fca3
Autor:
Wenhai Deng, Panpan Chen, Wen Lei, Yang Xu, Nengwen Xu, Jeffrey J. Pu, Aibin Liang, Wenbin Qian
Publikováno v:
Cancer Communications, Vol 41, Iss 9, Pp 925-929 (2021)
Externí odkaz:
https://doaj.org/article/efd6aefa0b5c4bd38119a89fe1ffd394
Autor:
Emmanuel K. Teye, Shasha Lu, Fangyuan Chen, Wenrui Yang, Thomas Abraham, Douglas B. Stairs, Hong-Gang Wang, Gregory S. Yochum, Robert A. Brodsky, Jeffrey J. Pu
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract Phosphatidylinositol glycan anchor biosynthesis class N (PIGN) has been linked to the suppression of chromosomal instability. The spindle assembly checkpoint complex is responsible for proper chromosome segregation during mitosis to prevent
Externí odkaz:
https://doaj.org/article/de2cadc6ed4e4474b1a7633bdd7d1cd8
Autor:
Dominic LaBella, Samuel Regan, Heiko Konig, Daniel N. Egan, Neil A. Bailey, Raya Mawad, Morgan Gilbert, John M. Pagel, Jeffrey J. Pu
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Acute Promyelocytic Leukemia (APL) is characterized by the t(15;17) chromosomal translocation resulting in a PML-RARA fusion protein. The all-trans-retinoic acid (ATRA) and Arsenic Trioxide (ATO) only regimens have demonstrated success in treating lo
Externí odkaz:
https://doaj.org/article/e3a605d3354d45f5be18821ef3ff9bac
Autor:
Jing-Zhou Hou, Jing Christine Ye, Jeffrey J. Pu, Hongtao Liu, Wei Ding, Hong Zheng, Delong Liu
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-25 (2021)
Abstract Antibodies and chimeric antigen receptor-engineered T cells (CAR-T) are increasingly used for cancer immunotherapy. Small molecule inhibitors targeting cellular oncoproteins and enzymes such as BCR-ABL, JAK2, Bruton tyrosine kinase, FLT3, BC
Externí odkaz:
https://doaj.org/article/4ad506c0875b4ed5a13225f361e23156
Autor:
Antonio Cuneo, Anthony R. Mato, Gian Matteo Rigolin, Alfonso Piciocchi, Massimo Gentile, Luca Laurenti, John N. Allan, John M. Pagel, Danielle M. Brander, Brian T. Hill, Allison Winter, Nicole Lamanna, Constantine S. Tam, Ryan Jacobs, Frederick Lansigan, Paul M. Barr, Mazyar Shadman, Alan P. Skarbnik, Jeffrey J. Pu, Alison R. Sehgal, Stephen J. Schuster, Nirav N. Shah, Chaitra S. Ujjani, Lindsey Roeker, Ester Maria Orlandi, Atto Billio, Livio Trentin, Martin Spacek, Monia Marchetti, Alessandra Tedeschi, Fiorella Ilariucci, Gianluca Gaidano, Michael Doubek, Lucia Farina, Stefano Molica, Francesco Di Raimondo, Marta Coscia, Francesca Romana Mauro, Javier de la Serna, Angeles Medina Perez, Isacco Ferrarini, Giuseppe Cimino, Maurizio Cavallari, Rosalba Cucci, Marco Vignetti, Robin Foà, Paolo Ghia, the GIMEMA, European Research Initiative (ERIC) on CLL, US study group
Publikováno v:
Cancer Medicine, Vol 9, Iss 22, Pp 8468-8479 (2020)
Abstract Limited information is available on the efficacy of front‐line bendamustine and rituximab (BR) in chronic lymphocytic leukemia (CLL) with reduced renal function or coexisting conditions. We therefore analyzed a cohort of real‐world patie
Externí odkaz:
https://doaj.org/article/51d4f3af2edb4e18930e0b7ba14d8eff